524715 Panoramica delle azioni Sun Pharmaceutical Industries Limited, azienda farmaceutica generica, sviluppa, produce e commercializza formulazioni di marca e generiche e ingredienti farmaceutici attivi (API) in India e a livello internazionale. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Sun Pharmaceutical Industries Limited Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Sun Pharmaceutical Industries Prezzi storici delle azioni Prezzo attuale dell'azione ₹1,841.50 Massimo di 52 settimane ₹1,960.20 Minimo di 52 settimane ₹1,249.80 Beta 0.60 Variazione di 1 mese 4.63% Variazione a 3 mesi -5.51% Variazione di 1 anno 45.92% Variazione a 3 anni 120.71% Variazione a 5 anni 322.99% Variazione dall'IPO 23,661.35%
Notizie e aggiornamenti recenti
Orexo Resolves Zubsolv US Patent Litigation with Sun Pharmaceutical Industries Dec 16
Price target increased by 8.8% to ₹2,023 Oct 30
Second quarter 2025 earnings: EPS exceeds analyst expectations Oct 29 Sun Pharma Presents LEQSELVI (deuruxolitinib) Data Highlighting Clinical Efficacy & Durability for Treatment of Alopecia Areata at the 2024 Fall Clinical Dermatology Conference
Sun Pharma Announces Multiple Data Presentations Highlighting Its Dermatology Portfolio to Be Featured At the 2024 Fall Clinical Dermatology Conference Oct 25
Sun Pharma Appoints Tejash Chheda as General Manager - Head of Media Sep 20 Vedi altri aggiornamenti
Orexo Resolves Zubsolv US Patent Litigation with Sun Pharmaceutical Industries Dec 16
Price target increased by 8.8% to ₹2,023 Oct 30
Second quarter 2025 earnings: EPS exceeds analyst expectations Oct 29 Sun Pharma Presents LEQSELVI (deuruxolitinib) Data Highlighting Clinical Efficacy & Durability for Treatment of Alopecia Areata at the 2024 Fall Clinical Dermatology Conference
Sun Pharma Announces Multiple Data Presentations Highlighting Its Dermatology Portfolio to Be Featured At the 2024 Fall Clinical Dermatology Conference Oct 25
Sun Pharma Appoints Tejash Chheda as General Manager - Head of Media Sep 20
Sun Pharma Introduces Novel Treatment, Tedizolid Phosphate in India for Acute Bacterial Skin and Skin Structure Infection Aug 23
Sun Pharmaceutical Industries Limited Approves Final Dividend for the Financial Year 2023-2024 Aug 06
Price target increased by 7.0% to ₹1,749 Aug 05
Price target increased by 7.2% to ₹1,746 Aug 04
Sun Pharmaceutical Industries Limited Receives Approval from U.S. Food and Drug Administration for LEQSELVITM (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata Jul 26
Sun Pharmaceutical Industries Limited to Report Q1, 2025 Results on Aug 01, 2024 Jul 16
Full year 2024 earnings: EPS exceeds analyst expectations Jul 10
Upcoming dividend of ₹5.00 per share Jul 05
Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) acquired remaining 21.5% stake in Taro Pharmaceutical Industries Ltd. (NYSE:TARO) from Krensavage Asset Management, LLC and others for approximately Jun 25
Sun Pharmaceutical Industries Limited Announces Results from A Phase 1, Multiple Ascending-Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Gl0034 (Utreglutide) in Obese Adults Jun 24
Sun Pharmaceutical Industries Limited, Annual General Meeting, Aug 05, 2024 Jun 20
Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) agreed to acquire 9.61% stake in HaystackAnalytics Pvt. Ltd. for INR 330 million. Jun 08
Full year 2024 earnings: EPS exceeds analyst expectations May 23
Sun Pharmaceutical Industries Limited to Report Q4, 2024 Results on May 22, 2024 May 15
Sun Pharmaceutical Industries Limited Announces Executive Changes Apr 03
Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) agreed to acquire 16.33% stake in Surgimatix, Inc for $3.1 million. Feb 20
Dividend increased to ₹8.50 Feb 02
Price target increased by 9.3% to ₹1,453 Feb 01
Third quarter 2024 earnings: EPS exceeds analyst expectations Feb 01
Sun Pharmaceutical Industries Limited Approves Interim Dividend for the Financial Year 2023-24, Payable on or Before February 23, 2024 Jan 31
Sun Pharmaceutical Industries Limited to Report Q3, 2024 Results on Jan 31, 2024 Jan 16
Sun Pharma Raises Offer to Buy Taro Pharmaceutical Industries' US Arm Dec 13
Sun Pharmaceutical Industries Limited Announces Management Changes Dec 07
Second quarter 2024 earnings: EPS exceeds analyst expectations Nov 02
Sun Pharmaceutical Industries Limited to Report Q2, 2024 Results on Nov 01, 2023 Oct 14
Sun Pharmaceutical Industries Limited Announces Presentation of Phase 4 Data Showed Sustained Improvement in Dry Eye Disease Signs and Symptoms in Patients Oct 13
Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) entered into agreement to acquire 37.76% stake in EzeRx Health Tech Pvt. Ltd. for INR 290 million. Oct 06
Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) signed a binding letter of intent to acquire remaining 25% stake in Sun Pharma de México, S.A. de C.V. from Indi Pharma S.A.P.I. de C.V. for approximately MXN 160 million. Sep 29
Sun Pharmaceutical Industries Limited Approves Final Dividend for the Financial Year 2022-2023 Aug 30
Sun Pharmaceutical Industries Limited Declares Final Dividend for the Financial Year 2022-2023 Aug 29
Sun Pharmaceutical Industries Looking to Fully Acquire Its Israel-Based Unit Taro Pharmaceutical Industries Aug 28
Price target increased by 7.0% to ₹1,229 Aug 07
Full year 2023 earnings: Revenues and EPS in line with analyst expectations Jul 30
Sun Pharmaceutical Industries Limited Appealed the Patent Litigation Decision Issued by the US District Court for the District of New Jersey Relating to Orexo's Patents Protecting ZUBSOLV® Jul 24
Upcoming dividend of ₹4.00 per share at 1.0% yield Jul 21
High number of new directors Jul 18
Sun Pharmaceutical Industries Limited to Report Q1, 2024 Results on Aug 03, 2023 Jul 12 Sun Pharmaceutical Industries Limited Propose Final Dividend for Fy2022-23, Payable on or Before September 8, 2023
Orexo AB (publ) Wins Patent Litigation for ZUBSOLV in the US Against Sun Pharmaceutical Industries Limited Jul 03
Sun Pharma Canada Inc. Announces Health Canada Approval of (PR)ABSORICA LD®? (Isotretinoin Capsules) for Treatment of Severe Nodular Acne Jun 27
Sun Pharmaceutical Industries Ltd. Presents Data from First-In-Human Phase 1 Studies of Gl0034 At the American Diabetes Association 83Rd Scientific Sessions Jun 26
Full year 2023 earnings: Revenues and EPS in line with analyst expectations May 27 Sun Pharmaceutical Industries Limited Announces Board Appointments
Sun Pharmaceutical Industries Limited to Report Q4, 2023 Results on May 26, 2023 May 12
Sun Pharmaceutical Industries Limited Provides Deuruxolitinib Clinical Program Update May 04
Whole Time Director recently sold ₹3.9m worth of stock Mar 22
Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) entered into agreement to acquire 27.39% stake in Remidio Innovative Solutions Pvt. Ltd. for INR 1.5 billion. Feb 20
Sun Pharmaceutical Industries Limited Announces US FDA Approval for Generic Lenalidomide Capsules Feb 11
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Feb 01 Sun Pharmaceutical Industries Limited Announces Retirement of Kalyanasundaram Subramanian as Whole-Time Director, Effective February 13, 2023
Sun Pharmaceutical Industries Limited Launches SEZABYTM (Phenobarbital Sodium) in the U.S. for the Treatment of Neonatal Seizures Jan 26
Sun Pharmaceutical Industries Limited to Report Q3, 2023 Results on Jan 31, 2023 Jan 17
Sun Pharmaceutical Industries Limited Announces One of Its Wholly-Owned Subsidiaries Launch A Novel Anti-Cancer Drug, Palbociclib in India for Patients Jan 12
Aurinia Pharmaceuticals Inc. Enters into Settlement Agreement with Sun Pharmaceutical Industries, Inc., Sun Pharmaceuticals Industries, Ltd., and Sun Pharma Global FZE Jan 04
Whole Time Director recently sold ₹9.2m worth of stock Dec 28
Insider recently sold ₹3.1m worth of stock Dec 10
Whole Time Director recently sold ₹10m worth of stock Nov 27
Sun Pharmaceutical Industries Limited and Sun Pharma Advanced Research Company Limited Announces U.S. FDA Approval of SEZABY (Phenobarbital Sodium Powder for Injection) for the Treatment of Neonatal Seizures Nov 19
Second quarter 2023 earnings: EPS exceeds analyst expectations Nov 02
Sun Pharmaceutical Industries Limited Approves the Appointment of Sanjay Asher as an Additional Director Designated as an Independent Director Nov 02
Sun Pharmaceutical Industries Limited to Report Q2, 2023 Results on Nov 01, 2022 Oct 11
Whole Time Director recently sold ₹14m worth of stock Sep 24
Upcoming dividend of ₹3.00 per share Aug 12
Sun Pharmaceutical Industries Limited Announces Retirement of Israel Makov as Chairman and Member of the Board Aug 05 Sun Pharmaceutical Industries Limited Recommends Final Dividend for the Year 2021-22, Payable on or Before September 20, 2022
First quarter 2023 earnings: EPS and revenues exceed analyst expectations Jul 30
Sun Pharmaceutical Industries Limited to Report Q1, 2023 Results on Jul 29, 2022 Jul 13
Sun Pharmaceutical Industries Limited Announces Cessation of Mr. Ashok I Bhuta as Compliance Officer Jun 02
Sun Pharmaceutical Industries Limited Recommends Final Dividend for the Year Ended March 31, 2022 May 31
Full year 2022 earnings: EPS misses analyst expectations May 31
Sun Pharmaceutical Industries Limited to Launch Brillo® in India May 19
Sun Pharmaceutical Industries Limited to Report Q4, 2022 Results on May 30, 2022 May 16
Executive Director recently sold ₹1.8m worth of stock Apr 03
Executive Director recently sold ₹14m worth of stock Mar 23 Sun Pharmaceutical Industries Limited Announces Change of Company Secretary and Compliance Officer
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Feb 01
Sun Pharma Receives DCGI Approval for Molxvir® (Molnupiravir) in India Dec 29
Whole Time Director recently sold ₹4.0m worth of stock Dec 28
A Federal Judge Denies All Motions for Summary Judgment in a Lawsuit Against Sun Pharmaceutical Industries Ltd and Ranbaxy Inc. in Generic Drug Overpricing Lawsuit Nov 24
Second quarter 2022 earnings released: EPS ₹8.50 (vs ₹7.56 in 2Q 2021) Nov 03
Whole Time Director recently sold ₹45m worth of stock Oct 03
Sun Pharma Launches Chericof® 12 in India, A Novel Formulation That Provides Relief from Cough for Up to 12 Hours Sep 30
Insider recently sold ₹167k worth of stock Sep 22
Non-Executive & Independent Director Vivek Sehgal has left the company Sep 08
Upcoming dividend of ₹2.00 per share Aug 16
Insider recently sold ₹1.0m worth of stock Aug 12
Price target increased to ₹826 Aug 03 Rendimenti per gli azionisti 524715 IN Pharmaceuticals IN Mercato 7D 1.0% 0.2% -2.5% 1Y 45.9% 38.1% 17.9%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 524715 ha superato il Indian Pharmaceuticals che ha restituito 38.1 % nell'ultimo anno.
Rendimento vs Mercato: 524715 ha superato il mercato Indian che ha restituito 17.9 % nell'ultimo anno.
Volatilità dei prezzi Is 524715's price volatile compared to industry and market? 524715 volatility 524715 Average Weekly Movement 2.6% Pharmaceuticals Industry Average Movement 6.0% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.1% 10% least volatile stocks in IN Market 4.1%
Prezzo delle azioni stabile: 524715 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 3% ) di 524715 è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 1983 43,000 Dilip Shanghvi www.sunpharma.com
Sun Pharmaceutical Industries Limited, azienda farmaceutica generica, sviluppa, produce e commercializza formulazioni di marca e generiche e ingredienti farmaceutici attivi (API) in India e a livello internazionale. L'azienda offre formulazioni in varie aree terapeutiche, tra cui sistema nervoso centrale, dermatologia, cardiologia, oncologia, neuropsichiatria, gastroenterologia, antinfettivi, diabetologia, dolore/analgesici, vitamine/minerali/nutrienti, apparato respiratorio, ginecologia, urologia, oftalmologia, ortopedia, nefrologia, odontoiatria e altre aree. Fornisce API per anticancro, peptidi, steroidi, ormoni e farmaci immunosoppressori.
Mostra di più Sun Pharmaceutical Industries Limited Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Sun Pharmaceutical Industries con la sua capitalizzazione di mercato? 524715 statistiche fondamentali Capitalizzazione di mercato ₹4.42t Guadagni(TTM ) ₹110.54b Ricavi(TTM ) ₹503.08b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 524715 Conto economico (TTM ) Ricavi ₹503.08b Costo del fatturato ₹112.67b Profitto lordo ₹390.41b Altre spese ₹279.87b Guadagni ₹110.54b
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) 46.07 Margine lordo 77.60% Margine di profitto netto 21.97% Rapporto debito/patrimonio netto 3.0%
Come si è comportato 524715 nel lungo periodo?
Vedi performance storica e confronto Dividendi
0.7% Rendimento attuale del dividendo
34% Rapporto di remunerazione
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2024/12/26 18:52 Prezzo dell'azione a fine giornata 2024/12/26 00:00 Guadagni 2024/09/30 Guadagni annuali 2024/03/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Sun Pharmaceutical Industries Limited è coperta da 73 analisti. 36 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Nitin Bhasin Ambit Capital Prashant Nair Ambit Capital null null Anand Rathi Shares and Stock Brokers Limited
Mostra 70 altri analisti 
